SICAGENBSESicagen India LtdMediumNeutral
Announced Mon, 8 Sept · 12:12 IST

21st Annual Report for the Financial Year 2024-25

Investor Communications View source PDF

SICAGEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Sicagen India Ltd has submitted its 21st Annual Report for FY 2024-25 to BSE, ahead of the AGM scheduled for September 30, 2025. Total revenue rose about 13% year-on-year to Rs. 54,603 lakhs from Rs. 48,304 lakhs, while profit before tax jumped nearly 65% to Rs. 2,002 lakhs (including Rs. 214 lakhs of exceptional items). Profit after tax grew about 64% to Rs. 1,453 lakhs, lifting EPS to Rs. 3.67 versus Rs. 2.24 in the previous year. The Board has recommended a higher dividend of 10% (against 6% earlier). The notice also covers the reappointment of Whole Time Director Nandakumar Varma for three years and appointment of a new Secretarial Auditor.

Likely market impact

The sharp rise in profits and a higher dividend payout are positive for shareholders. Note that Sicagen is now only listed on BSE, as NSE delisting took effect in July 2021, which may limit trading liquidity for retail investors.